The World Market for Diabetes Treatments

   Single User - $995
   Corporate License - $1,990

Published Oct 1, 2010 | 260 Pages | Pub ID: KLI2809047

This Kalorama Information report , The World Market for Diabetes Treatments, provides market estimates and forecasts for the world market for diabetes treatments. The diabetes market is one of the fastest growing markets within the pharmaceutical sector, and is one of the few pharmaceutical sectors that are likely to continue to grow at double digit rates throughout the forecast period. Major contributing factors to growth are increasing obesity and an aging worldwide population. The total market for diabetes treatments is divided into two major segments:
  • Insulin Markets in US, Europe, Japan, ROW
  • Oral Hypoglycemics in US, Europe, Japan, ROW
For each of these market segments the report provides market share and regional breakout (US, Europe, Asia, ROW). The report also discusses treatment for diabetes complications and natural and herbal treatments.

The report’s geographic scope is worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market. Trends covered in the report include:

  • New Products and the Development Pipeline (Afrezza, Bydureon, Syncria, AVE0010, Balaglitazone, Metgluna Otelixizumab and others)
  • Transplantation Research Efforts
  • Β-Cell Transplantation Research
  • Potential New Drug for Type 2 Diabetes
  • Insulin Pills
  • Three-month Insulin Shot
  • Outsourcing of Diabetes Projects
  • Reclassification of Cause of Death
Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets.

A market summary includes market analysis by product and region and a competitive analysis of leading providers. Additionally, key company profiles are included, including profiles of the following:

  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Eli Lilly & Co.
  • Merck
  • Metabolex, Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi-Aventis Group
  • Takeda Pharmaceutical Company Limited
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 25 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2009. Historical data was provided for the years 2008, with forecast data provided for 2010 through 2015. Compound annual growth rates (CAGRs) are provided for 2008-2015 periods for each region and/or segment covered. Competitive analysis is provided for the year 2009. The forecasted market analysis for 2009-2015 was largely based on demographic trends, new developments, innovative technology and global expansion.

In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times